Privia Health Appoints Lance V. Berberian to Board

By Philip Seaworth • Tuesday, July 08 10:18 • Permanent Link

Privia Health Group, Inc. (NASDAQ: PRVA) has announced the appointment of Lance V. Berberian to its board of directors, effective July 15, 2025. With this addition, the board will now comprise 10 directors. Berberian brings over 30 years of technology strategy and digital transformation experience, including expertise in IT governance, infrastructure management, and cybersecurity.

Prior to joining Privia Health, Berberian served as EVP and Chief Information and Technology Officer at Labcorp Holdings Inc. (NYSE: LH) until October 2024, where he oversaw a team of 5,000 people focused on IT strategy, cybersecurity, AI, product development, and data management. He has also held CIO roles at Idexx Laboratories, Kellstrom Aerospace, Interim Healthcare, and Quest Diagnostics.

Privia Health is one of the largest physician enablement companies in the United States, with a presence in 15 states and the District of Columbia. The company collaborates with medical groups, health plans, and health systems to optimize over 1,200 physician practices, improve the patient experience for more than 5.2 million patients, and reward over 4,800 physicians and advanced practitioners for delivering high-value care.

The company's mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. As a result of these announcements, the company's shares have moved -3.44% on the market, and are now trading at a price of $21.35. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.